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Summary. Targeting of immune cells by bispecific anti- 
bodies has proven a powerful tool for the investigation of
cellular cytotoxicity, lymphocyte activation and induction 
of cytokine production, as well as to represent an innova- 
tive form of immunotherapy for the treatment of cancer. 
The hallmark of this approach is the use of the specificity 
of monoclonal antibodies to join target and immune cells 
by virtue of the dual specificity of bispecific antibodies for 
the two entities. More precisely the bispecific antibody has 
two different binding sites, which are capable of recogniz- 
ing tumor associated antigens on the one hand and lympho- 
cyte activation sites on the other. This process of crosslink- 
ing results in the activation of the lymphocyte and trig- 
gering of its lytic machinery, as well as lymphokine pro- 
duction. A major advantage of this therapeutic modality is, 
that use is made of the normal cellular immune defence 
system and therefore is only associated with minor toxici- 
ty. The distinct lymphocyte populations, which can be used 
for adoptive immunotherapy and the various bispecific 
antibody preparations, as well as the chimeric immuno- 
globulin/T cell receptor construction are the major topics 
of this review. 
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Introduction 
The vertebrate immune system can eliminate and neutral- 
ize virtually any foreign invader and distinguish such an- 
tigens from the body's own. To this end we possess two 
major classes of immune responses: the humoral and the 
cellular responses. The humoral response is mediated by 
antibodies that are produced by B lymphocytes upon spe- 
cific antigen recognition. The binding of antibody to an- 
tigen facilitates the elimination of the invader by other 
immune cells. The cellular response involves specialized 
cells such as T lymphocytes and non-specific natural killer 
(NK) cells, monocytes, macrophages and granulocytes. 
The T lymphocyte population can be divided into two 
mutually exclusive subpopulations, i.e. TCRc~B and 
TCR78 lymphocytes. 
Experimentally induced tumour cells can express new 
antigens (Ag) on their surface. Such Ag are unique or 
selective and may be immunogenic and thus elicit a 
tumour-specific cytotoxic T lymphocyte (CTL) response. 
The study of tumour-specific immune reactions was stimu- 
lated by the postulation of immune surveillance as formu- 
lated by Ehrlich in 1909 [31], and adapted by Burnet in 
1970 [23]. The keynote of the hypothesis i that antigen- 
specific T lymphocytes are the critical surveillance cells 
that arrest or eliminate cancer cells from the host. In gener- 
al, specific T cells recognize their antigen in the context of 
the major histocompatibility complex (MHC) on the sur- 
face of the Ag-presenting cell. In experimentally induced 
tumour models such MHC-restricted tumour-specific 
T cells have been identified. In humans, "tumour-specific" 
CTL, which are not MHC-restricted, also have been 
demonstrated [22, 110]. 
Most efforts, however, to produce human CTL specific 
for human tumours have failed. Therefore the discovery 
that T cells can be recruited and targeted to a tumour cell 
by either bispecific antibodies (bs-mAb) or by equiping 
them with chimeric immunoglobulin/T cell receptors 
(Ig-TCR) has drawn considerable attention. These two 
strategies allow the focussing of immune effector cells to 
tumour cells and hold great promise for immunotherapy. 
CTL/target cell interaction. 
The interaction between a cytotoxic lymphocyte and a 
target cell can be divided into several stages [8, 67, 68]. 
The initial adhesion step is the rapid formation of an inter- 
cellular bond. Because CTL also bind to target cells that do 
not express the relevant MHC/antigen complex, and anti- 
TCR monoclonal antibodies (mAb) can not inhibit the 
initial binding step, it was concluded that the initial interac- 
tion does not involve a specific TCR/antigen interaction 
[94]. Blocking studies with mAb against cell-surface 
molecules have identified two major pathways of antigen 
non-specific nteractions [88]. First, leucocyte function-as- 
sociated antigen-1 (LFA-1 or CD11/18 a) on the surface of 
the effector cell interacts with intercellular adhesion mole- 
cule (ICAM)-I (CD54) or ICAM-2 [64, 65, 88, 96, 98]. 
Secondly, CD2 on the effector lymphocyte interacts with 
LFA-3 (CD 58) on the target cell [49, 87, 88]. When 
present on the surface of the cytotoxic lymphocyte, CD4 
and CD8 may also contribute to this initial adhesion by 
binding to MHC class II or class I molecules respectively 
[83, 92, 93]. The initial adhesion phase is dependent on the 
presence of Mg 2÷ [88]. The second stage of the cytotoxic 
process consists of target cell recognition, which results in 
stabilization of the interaction between the effector- and 
the target cell, and leads to effector cell activation. Target 
cell recognition and activation of T cells occur through the 
TCPUCD3 complex, in which the TCR is responsible for 
the antigen recognition and the CD3 molecule for the trans- 
duction of signals generated by the TCR-antigen interac- 
tion [25]. 
Stabilization of the interaction between the effector cell 
and the target cell is not only due to the extra TCR-antigen 
bond. TCR crosslinking also results in a transient confor- 
mational change of the LFA-1 molecule. Consequently, the 
LFA-1 mediated adhesion temporarily increases [30, 52]. 
In fact, crosslinking of TCR/CD3 complexes at the cell- 
cell contact region also induces changes in the conforma- 
tion and distribution of other cell surface molecules: 
TCR/CD3 crosslinking induces the redistribution of CD4 
or CD8 molecules, which lead these molecules towards the 
contact region, where they become physically associated 
with the TCR/CD3 complexes [11, 55, 85]. The intracellu- 
lar domains of CD4/CD8 antigens are also physically as- 
sociated with the lymphocyte specific tyrosine protein ki- 
nase (TPK) p56 lck. This TPK plays an important role in 
T cell activation, by phosphorylation f the ~ chain of the 
TCR/CD3 complex. 
The CD4/CD8 molecules, that are physically associated 
with TCR/CD3 complexes, are believed to bind to the same 
MHC molecule that presents the antigen, leading to an 
increased CTL-target cell binding and optimal CTL activa- 
tion [4, 85]. Taken together, it is clear that the co-clustering 
of TCR/CD3 with various other adhesion/signal transduc- 
tion molecules at the cell-cell contact region, and their 
physical and functional interactions, critically control acti- 
vation of the effector lymphocyte. The third stage of the 
cytotoxic process consists of the delivery of the lethal hit to 
the target cell and subsequent target cell death [114]. After 
delivery of the lethal hit, the effector lymphocyte dissoci- 
ates from the target cell and may bind to another, a process 
that is referred to as recycling [67, 68]. 
TCR o~fl and y~ lymphocytes 
The availability of anti-TCR/CD3 mAb has facilitated the 
elucidation of the protein structure of this receptor complex 
[28, 44, 66]. 
The TCR ÷ lymphocyte population comprises of two 
distinct lymphocyte populations which are both capable of 
exerting cell-mediated cytotoxicity: 
1. T lymphocytes that express an antigen-receptor, that is a 
disulphide-linked heterodimer composed of an o~ and a [3 
protein: TCR~z[3 lymphocytes [15]. 
2. T lymphocytes with an antigen-receptor c mposed of a y 
and a 8 protein. The y and 8 chains can be either disulphide 
or nondisulphide linked: TCRy8 lymphocytes [16, 20]. 
The TCRo~ and [3 genes encode transmembrane glyco- 
proteins whose sequences are homologous to those of Ig 
[45, 113]. Together, the TCRo~ and [3 chains determine the 
specificity of the TCRo~B lymphocytes [29, 84]. The TCR 
itself is thought not to be involved in signal transduction. In
fact, the TCR molecules are non-covalently associated 
with the CD3 molecular complex, which represent the 
signal-transducing structure [19, 74, 90]. 
T lymphocytes can also be activated by anti-TCPUCD3 
mAb. For activation to occur the mAb, and thereby the 
TCR/CD3 complexes, need to become crosslinked. Such 
Ab-induced T cell activation is polyclonal [61]. Crosslink- 
ing of the TCR/CD3 complex, either by antigen-specific 
stimulation or by anti-TCR/CD3 mAb, initiates signal 
transduction and leads to full T cell activation, expression 
of the interleukin-2 receptor (IL-2R), production of lym- 
phokines, cytolytic activity, and proliferation. As de- 
scribed, most TCRa[3 lymphocytes xpress either the CD4 
or CD8 molecules. The helper/inducer functions are ex- 
hibited by CD4 + lymphocytes, whereas CD8 +, and a 
minority of CD4 +, lymphocytes exert cytolytic activities 
[36, 63, 77]. The antigen specific recognition by CD4 + 
lymphocytes is restricted by MHC class II antigens, where- 
as that of CD8 + lymphocytes i  restricted by MHC class I
molecules [ 101 ]. The CD4/CD8 glycoproteins play distinct 
functions in T cell activation. Again, they stabilize or in- 
crease the avidity of the interaction of the TCR/CD3 com- 
plex and the Ag-MHC by binding to the same MHC mole- 
cule that presents the antigen. However they also play an 
important role as an independent signal transducing ele- 
ment. 
The cells of the minor TCRy8 lymphocyte fraction, 
(3%-4% of the TCR + lymphocytes) virtually all lack the 
expression of CD4 or CD8 antigens [16, 53, 99, 106]. 
Freshly isolated TCRy8 lymphocytes do not lyse NK sus- 
ceptible target cells. Upon in vitro activation, TCRy8 lym- 
phocytes can exert MHC-unrestricted cytolysis towards a 
variety of tumor cells of distinct histologic origin, which 
does not involve the TCR. Antigen specific TCRy8 lym- 
phocytes have also been identified. Some of the identified 
Og are CDlc, TCT-1, HLA-A2, A23, DR7 and Dw6 [95]. 
TCRy8 lymphocytes can be divided on the basis of their 
functional rearrangements into two distinct subsets. The 
V~9-V82 encoded TCRy8 heterodimer is the predominant 
receptor type in peripheral blood, whereas the VB1 en- 
coded TCRy8 heterodimer represents a minor population 
[99]. These distinct TCRy8 subpopulations show also dis- 
tinct MHC unrestricted activity towards uperantigens [35, 
100]. Superantigens are defined as structures that activate a
total lymphocyte population which uses one particular V 
gene element. 
Natural killer cells 
NK cells are lymphoid cells with typical "large granular 
lymphocyte" (LGL) morphology, and represent approxi- 
mately 10% of peripheral blood lymphocytes (PBL). NK 
cells are functionally defined by their ability to display 
cytotoxicity against various target cells without prior acti- 
vation [46, 75, 103]. They do not productively transcribe 
TCR genes [9, 58]. Therefore, their lytic activity is MHC- 
unrestricted. By definition, NK cells lack a memory re- 
sponse. In addition to their cytotoxic activity, a wide vari- 
ety of non-cytotoxic functions have been identified, e.g. 
the production of a plethora of cytokines in response to 
stimulation with lectins, viruses, bacteria or NK suscepti- 
ble target cells. The lymphokines produced by NK cells 
include interferonc~ and interferony (IFNo~, IFNy), IL-l, 
IL-2, natural killer cytotoxic factor, lymphotoxin and colo- 
ny stimulation factor (CSF). The capacity to produce this 
plethora of lymphokines illustrates their important im- 
munoregulatory role for NK cells [2, 80, 104, 112]. 
NK cells commonly express CD2, CD16 and NKHI 
(CD56) membrane antigens [81]. In contrast o TCRc~B 
lymphocytes, ingle anti-CD2 mAb preparations can in- 
duce cytotoxicity by NK cells in some target cell combina- 
tions, indicating that the CD2 alternative activation path- 
way is also functional in NK cells [14, 89]. The CD16 
(FcyRIII) molecule represents he low-affinity receptor for 
the Fc fragment of IgG, and is involved in antibody depen- 
dent cellular cytotoxicity (ADCC). The ability to mediate 
ADCC via CD 16 points to a signal-transducing capacity of 
CD16 [79, 105, l l l ] .  In NK cells the ~ chain is expressed 
in association with e CD16 molecule on the membrane 
and appears necessary for efficient surface expression of 
CD16 [5, 6, 59]. 
Non-TCR surface receptors involved in 
MHC-unrestricted cytolysis 
help for antibody responses, and induce antigen non-spe- 
cific cytolytic activity by CTL [14, 54, 109]. Single anti- 
CD2 mAb usually block c~ß T cell activation and prolifera- 
tion [10, 18]. Recently it has been shown that upon T cell 
activation via CD2, the CD2 is not only functionally but 
also physically associated with the CD3 molecular com- 
plex [21, 72]. 
Other nonpolymorphic glycoproteins, such as CD3, 
CD16, and CD28, are also involved in the lymphocyte 
activation and triggering for lysis. Some of these structures 
are functionally interrelated, or they interact with the 
TCRc~B, TCRy~ or putative NK lymphocyte receptor and 
with each other. This functional interplay between distinct 
activation sites suggests that their individual activation 
pathways, converge intracellularly [3, 13, 72, 105]. All 
data thus strongly argue in favor of our previously publish- 
ed hypothesis that a multireceptor recognition process is 
involved in MHC-(un)restricted target-cell recognition and 
lysis [47]. Therefore, activation via one receptor can be 
enhanced via another using combinations of the relevant 
mAb [13, 14, 17, 39, 76, 105]. 
Gene organisation and protein structure of the T cell 
receptor and immunoglobulins 
The structures present in the immunesystem, which are 
capable of specific antigen recognition are 1) the surface 
bound or secreted Ig on B cells and 2) the TCR expressed 
by T cells. The four distinct TCR chains c¢[3,y,6 form two 
different heterodimers (czB and y~). 
The genomic organization of the TCR elements re- 
sembles that of the immunoglobulin gene superfamily. 
Also their quaternary structure shows great similarity [28]. 
The putative receptors involved in MHC-unrestricted cyto- 
toxicity have not as yet been identified. It has been sug- 
gested that multiple receptors are involved in target cell 
recognition and MHC-unrestricted cytotoxicity: the multi- 
receptor model [47, 69]. In this model, lysis of target cells 
by activated lymphocytes can be triggered by the interplay 
of signals transduced by several cell-surface molecules that 
interact with their respective ligands on the target cell. The 
interactions between these molecules on the effector lym- 
phocyte and the relative xpression of their ligands on the 
target cell together determine whether or not the target cell 
will be lysed by the effector cell [12, 15, 47]. 
The CD2 molecules erve as a functionally important 
interaction structure on TCRc~B, TCRy8 and NK lympho- 
cytes. As detailed earlier, CD2 mediates the adhesion of 
the effector to the target cell via binding to its natural 
ligand, i.e. LFA-3 or CD58, thereby contributing to an- 
tigen non-specific lymphocyte activation [96]. Three 
functionally important epitopes, T11.1, T11.2 and T11.3, 
have been identified on CD2 [70]. Only combinations of 
mAb directed against he CD2 epitopes T11.2 and T11.3 
can induce IL-2 dependent aD T cell proliferation; provide 
TCR and lg genes 
Like the Ig light chain loci, the TCR c~ and y chain loci 
comprise anumber of variable gene s gments (V), joining 
gene segments (J) and one or more constant gene segments 
(C). The Ig heavy chain loci and the TCR [3 and ychain loci 
comprise additional diversity gene segments (D) between 
the V and J clusters [28, 91]. Functional TCR or Ig genes 
are assembled in an identical way in a two-step rocess of 
recombination. First, fusion of particular V, (D) and J 
segments within the DNA, by deletion of intervening 
sequences, creates a complete V-coding domain upstream 
of the C gene segment(s). Second, after transcription of the 
entire gene, RNA-splicing enzymes splice the non-coding 
intron that separates the V(D)J and C gene segments. The 
resulting sequence of messenger RNA is translated into 
protein. Diversity of TCR and Ig is not only created by the 
joining of particular V, (D), J and C gene segments but also 
by the random addition of nucleotides at the V-(D)-J join- 
ing sites [57]. The contribution of somatic mutations on 
diversity is, however, specific for Ig [28]. 
TCR and Ig protein structures 
Comparison of the primary sequence of TCR and Ig re- 
veals that the residues that are principally responsible for 
the framework structure of the V regions are highly con- 
served [27]. This implies that TCR and Ig V regions fold in 
the same fashion, and that the chain pairing and the result- 
ing combining sites of Vc~-V~ and Vy-V~ are similar to 
those of VH-VL combinations. The loops that form the 
antigen binding site in TCR are similar in size and location 
to those found in Ig but have different conformations. Also 
the structures at the V-C interphase of TCR and Ig are very 
similar, indicating that the V and C domains of TCR and Ig 
fold in the same way. Recently it has been found that 
membrane-bound Ig are associated with two other trans- 
membrane proteins, IgMo~ and Ig~, which form a disul- 
phide-linked heterodimer [48]. In analogy to the TCR/CD3 
relation, it was suggested that these proteins act as a signal 
transducer for the membrane bound Ig. 
Targeting of lymphocyte specificity 
Although most efforts to produce human CTL specific for 
human tumours have failed, many mAb are available that 
bind selectively, albeit not exclusively, to tumour cells. 
The combined use of CTL and tumour-selective mAb, 
offered a novel approach to target he CTL to the tumor 
cells selectively. These engineered lymphocyte specifici- 
ties may in the future play a key role in the destruction f 
tumour cells. The employment of (a) mAb, (b) bs-mAb or 
(c) chimeric Ig-TCR receptors to engineer lymphocyte 
specificity for targeting to tumour cells together with cy- 
tokines represents a promising approach. 
for example one specific for a given tumour-cell-as- 
sociated antigen. Also chemically crosslinked antibodies 
have been produced with one binding site recognizing the 
CD 16 activation site on NK cells and the other ecognizing 
a tumour-associated antigen [50]. Such mAb heteroaggre- 
gates bridge the effector lymphocyte tothe target cell (con- 
jugate formation) and trigger the lymphocyte lytic machin- 
ery. In the latter example the heteroconjugated antibody 
triggers lymphocyte-mediated cytolysis by binding to 
CD16 via its Fab, rather than via its Fc portion. 
Along the same line, many preparations ofbs-mAb, that 
recognize the CD3 complex on the one hand and a tumour- 
associated antigen on the other (e.g. melanoma, renal, 
ovarian, lung and mammary carcinoma) have been 
developed [24, 60, 102, 106, 107]. Such bs-mAb have also 
been generated by fusion of two hybridomas that produce 
CD3/TCR-specific mAb or the target-cell-specific mAb 
respectively [711. The hallmark of bs-mAb targeting isthat 
the binding of the bs-mAb to the, by their nature uniquely, 
specific CTL now targets the CTL with the bs-mAb speci- 
ficity. These bs-mAb-targeted CTL can effectively be used 
for adoptive transfer of immunity [86]. 
Since mAb with specificity for particular lymphocyte 
activation sites exist that trigger different functions or lym- 
phocyte subpopulations, their selective use allows the acti- 
vation and expansion of particular subsets of lymphocytes 
and eliminates the need for prior isolation of these lympho- 
cyte subsets. These laboratory-targeted immune lympho- 
cytes are presently being used for locoregional clinical 
adoptive immunotherapy. We and others have recently 
started a phase I-II clinical trial employing bs-mAb-retar- 
geted lymphocytes for the intraperitoneal treatment of 
ovarian carcinoma patients [73]. 
Monoclonal antibody targeting of cytotoxic 
T Iymphocytes 
As earlier detailed, CTL can only lyse target cells that 
express the r levant Ag/MHC complex on their cell sur- 
face. However, CTL can also be induced to lyse target cells 
that they would normally not recognize and lyse [105]. 
This process is referred to as targeting of lymphocytes. For 
instance, anti-TCR/CD3 mAb can mimic the activation 
that occurs upon TCR-Ag/MHC recognition. Anti- 
TCR/CD3 mAb induces lysis of IgG-Fc-receptor-positive 
target cells because the mAb bridges the CTL and the 
target cell, and simultaneously activates the lytic machin- 
ery of the CTL [62, 105]. Also mAb directed against other 
activation sites, such as CD2, CD16 and CD26, can induce 
lysis of target cells [14, 37, 38, 105]. 
Bispecific mAb targeting of cytotoxic T lymphocytes 
An interesting exploitation of the phenomenon that mAb 
mediated lymphocyte activation results in triggering of the 
lytic machinery (see above) is the use of bs-mAb [78, 97]. 
Bs-mAb can be produced by chemically coupling a mAb 
that is pecific for, e. g. the TCR complex to a second mAb, 
Chimeric immunoglobulin-T cell receptor 
Bs-mAb-targeted T lymphocytes retain the antibody-dic- 
tated specificity only for limited periods of time (6-72 h), 
due to the dissociation of the bs-mAb from the cell surface 
[60] (Bolhuis, manuscript in preparation). In addition, it s
not known whether the bs-mAb targeted lymphocytes can 
traffic, and eventually home to the tumour site. Thus, the 
bs-mAb targeted T lymphocytes may t this stage be ther- 
apeutically most effective when applied locoregionally. 
The systemic eradication of primary tumours and metasta- 
sis requires "long-lasting" and systemic immune re- 
sponses. Molecular engineering of T lymphocytes can re- 
sult in such permanently acquired, laboratory chosen, 
tumour selectivity of T lymphocytes, i.e. by the construc- 
tion of chimeric Ig-TCR receptors. To become ffective, 
such T lymphocytes require not nly the stable expression 
of the engineered Ig-TCR receptor at the lymphocyte sur- 
face, but also its functional association with t e CD3 sig- 
nal-transducing elements. This condition was met by the 
introduction and expression of chimeric Ig/TCR genes, in 
which the variable (V) gene segments of the TCRa and 
TCRI] chains were replaced by the variable gene segments 
of the heavy and light chain of an Ig with known specificity 
17, 32, 41-431. 
Transfection of  the expression vectors containing these 
chimeric Ig/TCR genes in recipient mouse T cell lines re- 
sulted in the synthesis of chimeric proteins which became 
stably and functionally expressed at the lymphocyte sur- 
face of  the lymphocytes. Both combinations of  com- 
plementary chimeric Ig/TCR genes, i. e. VI4- Cc~ + VL-C~3 
or VH-C~3 +VL-Co~, appeared to yield a functional 
chimeric heterodimer [43, 56]. Consequently, the chimeric 
receptor equiped the T lymphocytes with the antibody 
specificity which, of course, is MHC-unrestricted. These 
chimeric receptors were able to transduce signals for T cell 
activation, as determined by Cai 2÷ mobilization [56]; IL-2 
production [32, 40-43] ;  proliferative response [40], and 
cytotoxic activity [40, 42, 43]. 
Relatively large numbers of lymphocytes expressing the 
chimeric receptor are required for therapeutic applications. 
In order to reduce the need for prolonged lymphocyte 
expansion, it is important hat a high percentage of lym- 
phocytes can simultaneously be infected. Such a high mul- 
tiplicity of infection also ensures that the genetically mod- 
ified T cells are polyclonal. This may be best achieved by 
retrovirus-mediated gene transfer, which can transduce a
wide variety of cell types with a much higher efficiency 
than other procedures [26]. Another advantage of retro- 
virus-mediated gene transfer is that all proviral copies be- 
come stably integrated into the chromosomal DNA of the 
recipient cell. This chromosomal integration of the trans- 
duced gene guarantees the constitutive expression of  
chimeric Ig/TCR genes, a prerequisite for prolonged im- 
mune reactivity. Meanwhile, mouse and human T lympho- 
cytes have been successfully transduced with a number of 
genes using retroviral vectors [1, 26, 33, 34, 51, 82]. 
Before clinical application of these genetically modified 
lymphocytes takes place we have to know whether the 
administration of these lymphocytes i safe. After all, for- 
eign DNA is inserted randomly in the genome and this may 
theoretically initiate an oncogenic transformation. How- 
ever, the results obtained in vitro in animals and those 
obtained after and during 56 months of  observation of 
patients who received Neo-gene transfected autologous 
T lymphocytes in a phase I clinical protocol, have not 
revealed any abnormalities or side-effects. 
Concluding remarks 
The targeting of  immune effector cells to tumour cells by 
bs-mAb or by chimeric Ig-TCR receptors offers potential 
clinical applications. Many questions till need to be ans- 
wered: 
Is the triggering for cytolysis by CTL important or is the 
induction of lymphokine production by CTL or non-CTL 
critical? 
Can the targeted CTL traffic and home like physiologi- 
cally activated T cells? Does lymphokine production at the 
tumour site cause "bystander" tumour cell lysis which pre- 
vents the escape of those tumour cells that lack the relevant 
tumour antigen expression? 
Does "humanization" of the mouse mAb prevent or 
reduce human anti-mouse Ab responses that may block 
their therapeutic effect? 
What are the optimal time schedules for administration 
of adoptive immunotherapy? 
Data addressing these different questions are emerging. 
However, we should not delay clinical studies until all the 
questions have been answered, provided of course that the 
trials fulfil the accepted criteria of  good laboratory and 
clinical practice. 
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